Menu Search
Equities

BICO Group AB

BICO:STO

BICO Group AB

Actions
Health CareMedical Equipment and Services
  • Price (SEK)36.40
  • Today's Change1.78 / 5.14%
  • Shares traded173.95k
  • 1 Year change-32.47%
  • Beta1.9138
Data delayed at least 15 minutes, as of Nov 22 2024 17:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy0
Outperform3
Hold0
Sell0
Strong Sell0

Share price forecast in SEK

The 3 analysts offering 12 month price targets for BICO Group AB have a median target of 100.00, with a high estimate of 100.00 and a low estimate of 85.00. The median estimate represents a 174.73% increase from the last price of 36.40.
High174.7%100.00
Med174.7%100.00
Low133.5%85.00

Earnings history & estimates in SEK

On Aug 20, 2024, BICO Group AB reported 2nd quarter 2024 losses of -1.10 per share.
The next earnings announcement is expected on Nov 26, 2024.
Average growth rate-289.00%
BICO Group AB reported annual 2023 losses of -28.10 per share on Feb 20, 2024.
Average growth rate-169.26%
More ▼

Revenue history & estimates in SEK

Cellink AB (publ) had 2nd quarter 2024 revenues of 534.00m. This missed the 549.60m consensus estimate of the 2 analysts following the company. This was 6.65% above the prior year's 2nd quarter results.
Average growth rate+0.43%
Cellink AB (publ) had revenues for the full year 2023 of 2.25bn. This was 0.46% above the prior year's results.
Average growth rate+229.92%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.